Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026 - Research and Markets

Research and Markets
Posted on: 19 Aug 16

Research and Markets has announced the addition of the "Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026" report to their offering.

The Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016-2026, report provides a comprehensive analysis of the current market landscape of these therapies and an informed opinion on how the market is likely to evolve over the next decade. The anti-diabetic drugs market broadly comprises of insulin and non-insulin therapies.

Non-insulin therapies are further classified under various categories based on their respective mechanisms of action. Of the different types of non-insulin therapies, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors have been the most popular in the last few years. As mentioned earlier, these therapeutic classes have captured the attention of a number of pharmaceutical companies and drug developers worldwide.

Several companies, including pharmaceutical giants, mid-sized players and start-ups, have come up with innovative technologies and novel formulations of these drug classes. Such advances have generated and sustained significant momentum in this segment of the industry.

Specifically, GLP-1 agonists, which have been researched for several years, have a rich pipeline of clinical and preclinical molecules. DPP4 inhibitors currently have a relatively larger market share; however, they are now giving way to other relatively newer and emerging classes such as SGLT2 inhibitors.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. GLP-1 Agonists

6. DPP4 Inhibitors / CD26 Antigen Antagonists

7. SGLT2 Inhibitors

8. Discontinued Molecules and Common Side Effects

9. Novel Non-Insulin Therapies for Diabetes

10. Market Forecast

11. Publication Analysis

12. KOL Analysis

13. Interview Transcripts

14. Conclusion

Companies Mentioned:

  • 3SBio
  • Aalborg Hospital
  • Aarhus University Hospital
  • Abbott Laboratories
  • ActivX Biosciences
  • Addex Therapeutics
  • Aegis Therapeutics
  • AGDUC
  • AIDS Clinical Trials Group
  • Ajinomoto
  • Alantos Pharmaceuticals
  • Albert Einstein College of Medicine
  • Alize Pharma
  • Alkem Labs
  • Alkermers
  • Allegheny Health Network
  • Allergan
  • Almirall
  • Alteogen
  • ALZA Pharmaceuticals
  • (400+ More)

For more information about this report visit http://www.researchandmarkets.com/research/7dbzr3/noninsulin.

Related Topics: Immune Disorders Drugs, Endocrinology

View source version on businesswire.com: http://www.businesswire.com/news/home/20160819005652/en/

Business Wire
www.businesswire.com

Last updated on: 19/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.